CLA-1816 / Claritas Pharma - LARVOL DELTA

Kalytera issues CEO letter to shareholders (GlobeNewswire) - "KAL-1816 for Treatment of Pain: Kalytera’s molecule in development for treatment of pain, KAL-1816, has been shown in laboratory testing to strongly and selectively bind with and activate the alpha3 glycine pain receptor....There are four enantiomers of KAL-1816. The next steps in the development of KAL-1816 will involve further laboratory work to determine the most potent enantiomer of this molecule. Following completion of this...our strategy will be to advance this compound through Phase 1 and Phase 2 clinical testing, and then seek to out-license or sell the program."

Preclinical • Pain

Kalytera Announces Additional Progress with Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain (GlobeNewswire, Kalytera Therapeutics Inc.) - "Kalytera Therapeutics, Inc....today announced that it has invented a novel first-in-class cannabinoid molecule, designated KAL-1816, that strongly and selectively binds with and activates the alpha3 glycine pain receptor. Activation of the alpha3 glycine receptor shuts down pain transmission in inflammatory conditions, such as arthritis, colitis, and sciatica....Kalytera will now advance KAL-1816 into a series of IND-enabling studies to be conducted over the next year. These investigations will include in vivo efficacy studies, pharmacokinetic studies, and safety studies, all of which will be required by the FDA for commencement of a Phase 1 human clinical study in the treatment of pain."

Preclinical